Allied Market Research Reveals $14.84+ Billion Compounding Pharmacies Market with 6.2% CAGR

𝘛𝘩𝘦 𝘨𝘭𝘰𝘣𝘢𝘭 𝘤𝘰𝘮𝘱𝘰𝘶𝘯𝘥𝘪𝘯𝘨 𝘱𝘩𝘢𝘳𝘮𝘢𝘤𝘪𝘦𝘴 𝘮𝘢𝘳𝘬𝘦𝘵 𝘪𝘴 𝘱𝘳𝘰𝘱𝘦𝘭𝘭𝘦𝘥 𝘣𝘺 𝘢 𝘤𝘰𝘯𝘷𝘦𝘳𝘨𝘦𝘯𝘤𝘦 𝘰𝘧 𝘧𝘢𝘤𝘵𝘰𝘳𝘴, 𝘪𝘯𝘤𝘭𝘶𝘥𝘪𝘯𝘨 𝘵𝘩𝘦 𝘳𝘪𝘴𝘪𝘯𝘨 𝘪𝘯𝘤𝘪𝘥𝘦𝘯𝘤𝘦 𝘰𝘧 𝘤𝘩𝘳𝘰𝘯𝘪𝘤 𝘥𝘪𝘴𝘦𝘢𝘴𝘦𝘴, 𝘢 𝘣𝘶𝘳𝘨𝘦𝘰𝘯𝘪𝘯𝘨 𝘦𝘭𝘥𝘦𝘳𝘭𝘺 𝘱𝘰𝘱𝘶𝘭𝘢𝘵𝘪𝘰𝘯, 𝘢𝘯𝘥 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘮𝘦𝘯𝘵𝘴 𝘪𝘯 𝘭𝘪𝘧𝘦 𝘦𝘹𝘱𝘦𝘤𝘵𝘢𝘯𝘤𝘺.

Allied Market Research recently released a comprehensive report titled “Compounding Pharmacies Market by Therapeutic Area, Route of Administration, and Sterility: Global Opportunity Analysis and Industry Forecast, 2021-2031.” This report forecasts significant growth in the global compounding pharmacies industry, estimating its value at $8.12 billion in 2021 and projecting it to reach $14.84 billion by 2031, with a compound annual growth rate (CAGR) of 6.2% from 2022 to 2031. The report provides detailed insights into evolving market trends, key segments, prominent investment opportunities, the value chain, competitive dynamics, and regional variations.

Download Report (245 Pages PDF with Insights, Charts, Tables, Figures): https://www.alliedmarketresearch.com/request-sample/12285

The global compounding pharmacies market experiences several drivers, restraints, and opportunities shaping its trajectory. The rise in chronic diseases, coupled with an aging population and improved life expectancy, fuels market growth. Additionally, the alarming increase in drug failure rates and widespread drug shortages globally further stimulate market expansion. However, heightened restrictions on manufacturing complex formulations pose challenges to growth. Nonetheless, the market benefits from significant growth prospects in emerging economies, presenting ample opportunities for advancement.

By 2031, the pain management segment is projected to maintain its dominance in the global compounding pharmacies market, owing to factors such as the growing elderly population, increased surgical procedures, and rising healthcare expenditure worldwide. In 2021, this segment already accounted for nearly two-fifths of the market share. Meanwhile, the others segment is anticipated to experience the fastest compound annual growth rate (CAGR) of 7.3% from 2022 to 2031, driven by the rising incidence of neurological disorders and cancer cases.

In terms of route of administration, the oral segment is poised to continue its dominance, contributing over two-fifths of the market revenue in 2021 and expected to maintain its lead through 2031. This is attributed to the wide availability of orally administered medications. Conversely, the others segment is forecasted to witness the fastest CAGR of 6.7% from 2022 to 2031, fueled by factors such as increased product affordability, a growing elderly population, and rising consumer acceptance of compounding medications.

Regarding sterility, the non-sterile compounding drugs segment held more than two-thirds of the market share in 2021 and is anticipated to uphold its dominance by 2031. This segment is also expected to exhibit the fastest CAGR of 6.5% from 2022 to 2031, driven by factors such as the rising prevalence of chronic diseases like diabetes, the growing demand for personalized medicines, and the increasing elderly population globally.

In 2021, North America emerged as the leading region in the global compounding pharmacies market, accounting for over half of the market share. This dominance is attributed to the region’s well-established healthcare system, growing population of elderly patients, and supportive reimbursement policies. Meanwhile, Asia-Pacific is expected to achieve the fastest compound annual growth rate (CAGR) of 7.3% by 2031. Factors such as the burgeoning medical tourism industry and increasing public awareness of the advantages of compounding medications are driving market growth in this region.

Key players in the industry-

• Athenex Pharma Solutions
• B. Braun Melsungen AG
• Fresenius SE and Co. KGaA
• Advanced Pharmacy
• McGuff Companies, Inc.
• Nephron pharmaceuticals
• RX3 compounding pharmacy
• Valor Compounding Pharmacy
• ITC compounding pharmacy
• Dougherty’s Pharmacy, Inc.
• Rx express compounding pharmacy
• Perrigo Company Plc (Fagron)
• New Compounding Pharma
• Institutional pharmacy solutions
• Olympia Compounding Pharmacy
• Panacea Biomatx Inc (Triangle Compounding Pharmacy)
• Pencol compounding pharmacy

Purchase Inquire:
https://www.alliedmarketresearch.com/purchase-enquiry/12285